Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue (GHS) and a selective agonist of the ghrelin receptor, formally designated as the growth hormone secretagogue receptor type 1a (GHS-R1a). The compound was developed in the late 1990s by researchers at Novo Nordisk as part of a broader investigation into synthetic growth hormone releasing peptides (GHRPs), with early published work appearing in the scientific literature beginning in 1998. Unlike earlier members of the GHRP class, Ipamorelin was characterized in preclinical research as demonstrating a high degree of selectivity for growth hormone release relative to other pituitary hormones, a property that distinguished it from earlier compounds in the same class and made it a subject of continued scientific interest. The compound’s well-defined receptor binding profile and relatively simple pentapeptide structure have contributed to its utility as a research tool in preclinical investigations of the somatotropic axis and related biological systems. Ipamorelin is available for research purposes and is not intended for human or veterinary use.

Chemical and Structural Profile

Ipamorelin has the molecular formula C38H49N9O5 and a molecular weight of approximately 711.9 daltons. Its amino acid sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a synthetic pentapeptide configuration that incorporates several non-natural amino acid residues, including alpha-aminoisobutyric acid (Aib) at the N-terminus and D-2-naphthylalanine (D-2-Nal) at the third position. These non-natural residues were incorporated during the compound’s development to confer resistance to enzymatic degradation and to optimize receptor binding selectivity, distinguishing Ipamorelin structurally from endogenous peptides and earlier synthetic GHRPs.

The compound is classified as a linear synthetic pentapeptide and does not contain disulfide bonds or cyclic structural elements. Its C-terminal amidation, denoted by the NH2 designation in the sequence, is a structural feature that contributes to its stability relative to non-amidated analogs and is reproduced in research-grade synthetic preparations. Published pharmacokinetic research conducted in rodent and porcine models has reported a relatively short circulating half-life for Ipamorelin, consistent with the general pharmacokinetic profile of peptide-based compounds, though the precise values reported vary across studies and experimental conditions.

In research-grade form, Ipamorelin is typically supplied as a lyophilized white powder. Lyophilization preserves structural integrity during storage and protects against hydrolytic degradation that can occur in aqueous solution over time. The presence of non-natural amino acid residues in the Ipamorelin sequence confers greater resistance to proteolytic degradation compared to peptides composed entirely of natural L-amino acids, a property that is relevant to its handling and stability characteristics in laboratory settings. High-performance liquid chromatography (HPLC) is the standard analytical method for purity assessment in research-grade preparations, with mass spectrometry used to confirm molecular identity and verify the structural features characteristic of the compound.

Mechanism of Action

The mechanistic research on Ipamorelin is centered on its activity as a selective agonist at the GHS-R1a receptor, a G protein-coupled receptor that is expressed in the pituitary gland, hypothalamus, and a range of peripheral tissues. Published receptor binding studies have characterized Ipamorelin’s affinity for GHS-R1a and demonstrated selective engagement of this receptor relative to other pituitary hormone pathways, a finding reported by Raun and colleagues in their foundational 1998 publication in the European Journal of Endocrinology. Receptor binding at GHS-R1a initiates intracellular signaling through the Gq/11 protein pathway, leading to activation of phospholipase C and subsequent generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), which together mediate an increase in intracellular calcium concentration. This calcium-dependent signaling cascade has been proposed in the published literature as the primary mechanism underlying the growth hormone secretory responses observed in preclinical research models following Ipamorelin administration.

Animal model studies, primarily conducted in rats and pigs, have examined the downstream endocrine effects associated with GHS-R1a activation by Ipamorelin. Published research has reported dose-dependent stimulation of growth hormone release from the anterior pituitary in these animal models, without the concomitant elevations in cortisol, prolactin, or adrenocorticotropic hormone (ACTH) that were observed with earlier synthetic GHRPs such as GHRP-6. This selectivity profile was a key finding of the early Ipamorelin research program and has been consistently reported across multiple preclinical publications. The mechanism by which Ipamorelin achieves this selectivity relative to earlier GHRPs has been attributed in the literature to its distinct structural features, particularly the D-2-Nal residue at position three, which appears to confer receptor subtype selectivity through specific ligand-receptor contact interactions.

Downstream of growth hormone release, animal model research has examined the effects of Ipamorelin on insulin-like growth factor 1 (IGF-1) levels in rodent models, with published studies reporting elevations in circulating IGF-1 following repeated administration in experimental animals. The IGF-1 axis has been a subject of considerable research interest in the context of somatotropic biology, and Ipamorelin’s ability to engage this axis in preclinical models through GHS-R1a activation has informed subsequent research examining the compound in various tissue and metabolic research contexts.

Key Research Areas

Somatotropic Axis and Growth Hormone Secretion Research

The most extensively published research area for Ipamorelin involves its activity at the somatotropic axis, specifically its capacity to stimulate growth hormone secretion through GHS-R1a agonism in preclinical animal models. Raun and colleagues (1998), in the foundational European Journal of Endocrinology publication, characterized the growth hormone secretory profile of Ipamorelin in rat and porcine models, establishing the selectivity profile that distinguishes this compound from earlier GHRPs. Subsequent published studies have examined the dose-response relationship between Ipamorelin administration and growth hormone secretion in rodent models, alongside investigations of receptor desensitization and pulsatile secretory patterns under repeated administration conditions in experimental animals. This body of work represents the most substantive and independently replicated portion of the Ipamorelin research literature and forms the scientific foundation for its continued use as a research tool in somatotropic biology investigations.

Bone Density and Skeletal Research

A subset of published preclinical research has examined Ipamorelin in the context of skeletal biology, with animal model studies investigating the compound’s effects on bone formation parameters in rodent models. Svensson and colleagues published research examining Ipamorelin in ovariectomized rat models, a standard preclinical model used in skeletal research, reporting on bone mineral density and bone formation markers measured in treated versus control animals. Additional published studies have examined the relationship between GHS-R1a agonism and osteoblast activity in cell culture systems, with some in vitro research reporting on markers of bone cell proliferation and differentiation in treated cultures. The skeletal research literature for Ipamorelin is smaller in volume than the somatotropic axis literature but represents a distinct and published area of preclinical investigation that has informed broader research interest in growth hormone secretagogues as research tools in bone biology.

Gastrointestinal Motility Research

Published preclinical research has examined Ipamorelin and related GHS-R1a agonists in the context of gastrointestinal motility, reflecting the established expression of GHS-R1a receptors in enteric nervous system tissues and gastrointestinal smooth muscle. Trudel and colleagues published research examining the effects of GHS-R1a agonism on gastric emptying and intestinal transit in rodent models, with findings reported on motility parameters under both normal and experimentally altered gastrointestinal conditions. The gastrointestinal research area for GHRPs including Ipamorelin reflects growing scientific interest in the peripheral roles of the ghrelin receptor system beyond its pituitary functions, and published research has examined the compound in this context as a tool for investigating enteric GHS-R1a biology. This research area remains less fully developed than the somatotropic literature and represents an active area of ongoing preclinical investigation.

Metabolic and Body Composition Research

Animal model studies have examined Ipamorelin in metabolic research contexts, with published research investigating parameters related to body composition, adipose tissue distribution, and energy metabolism in rodent experimental models. The IGF-1 axis engagement observed in somatotropic research has provided a mechanistic rationale for examining Ipamorelin in metabolic model systems, given the established role of growth hormone and IGF-1 signaling in lipid and carbohydrate metabolism as characterized in the broader endocrinology literature. Published rodent studies have examined body weight, lean mass, and fat mass parameters in animals receiving Ipamorelin under various experimental conditions, with findings reported alongside measurements of circulating growth hormone and IGF-1 as mechanistic markers. These metabolic research findings are preliminary in the context of the overall Ipamorelin literature and require further investigation in more complex experimental systems before their implications can be fully evaluated.

Research Considerations for Laboratory Use

Research-grade Ipamorelin is supplied as a lyophilized powder and requires specific storage conditions to maintain compound integrity for experimental use. Long-term storage at -20 degrees Celsius or below is recommended, with desiccation to minimize moisture exposure during storage. The non-natural amino acid residues incorporated into the Ipamorelin sequence confer greater resistance to enzymatic degradation than is typical of natural peptides, but the compound remains susceptible to hydrolytic degradation in aqueous solution and to physical instability associated with repeated freeze-thaw cycling of reconstituted preparations. Researchers should plan experimental workflows accordingly, preparing reconstituted aliquots sized for single experimental use where possible.

For laboratory reconstitution, sterile water or bacteriostatic water is the standard solvent used in research settings, with the reconstitution volume determined by the concentration requirements of the specific experimental protocol. Reconstituted Ipamorelin solutions are generally maintained at 4 degrees Celsius for short-term experimental use, with storage periods kept to a minimum to preserve compound integrity. The selection of reconstitution solvent and storage conditions should be guided by the experimental design and applicable institutional research protocols rather than any fixed preparation guideline.

Purity specification is a critical procurement consideration for Ipamorelin research, as the presence of synthetic impurities or incomplete reaction byproducts from peptide synthesis can confound receptor binding assays and downstream biological measurements. Research-grade Ipamorelin should be accompanied by a lot-specific certificate of analysis (COA) from an independent third-party testing laboratory, with purity verified by HPLC to a specification of 99% or greater. Given the structural complexity of Ipamorelin relative to simpler linear peptides, mass spectrometry confirmation of molecular identity is particularly important to verify the presence of the non-natural amino acid residues and C-terminal amidation that define the compound’s structure. Researchers should request and review COA documentation from independent laboratories prior to procurement to ensure analytical confidence in the research material being used.

Published Literature and References

The published literature on Ipamorelin is well established relative to many synthetic research peptides, with a body of work spanning from the foundational receptor characterization studies of the late 1990s through subsequent preclinical investigations across multiple biological systems. The somatotropic axis and growth hormone secretion literature represents the most extensively developed and independently replicated portion of the published record, while skeletal, gastrointestinal, and metabolic research areas represent smaller but substantive contributions to the overall literature. The majority of published studies have been conducted in rodent and porcine animal models, with supporting in vitro research in cell culture systems. Human clinical research on Ipamorelin remains limited in the published record, and the existing literature is explicitly preclinical in scope. This article is a research overview compiled from published scientific sources and does not constitute medical advice. All referenced studies were conducted in preclinical settings and further research is ongoing.

References:

Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH, 1998. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PMID: 9849822

Svensson J, Lall S, Dickson SL, Bengtsson BA, Romer J, Ahnfelt-Ronne I, Ohlsson C, Jansson JO, 2000. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. PMID: 10657022

Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH, 1998. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry. PMID: 9599238

Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A, 2005. Growth hormone deficiency and excess in rodent models of kidney disease. Growth Hormone and IGF Research. PMID: 15519921

Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P, 2002. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. American Journal of Physiology – Gastrointestinal and Liver Physiology. PMID: 12456388

Bowers CY, 1998. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. PMID: 9529905

Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E, 2002. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. European Journal of Pharmacology. PMID: 12208312

---

This article is intended for informational and research reference purposes only. Ipamorelin is sold strictly for laboratory and research use. It is not intended for human or veterinary consumption, and this content does not constitute medical advice, treatment recommendations, or clinical guidance. All research applications referenced in this article are based on preclinical literature. Researchers should consult applicable regulations and institutional guidelines before use.